Vivitrol is approved for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to treatment initiation. Alkermes, Inc., and Cephalon, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved prescription medication Vivitrol (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence. Vivitrol is the first once-monthly injectable medication for alcohol dependence. Vivitrol is indicated for alcohol dependent patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. Treatment with Vivitrol should be used in combination with psychosocial support, such as counseling or group therapy.

Vivitrol mechanism of action
Vivitrol works by binding to opioid receptors in the brain. Although the mechanism responsible for the reduction in alcohol consumption observed with Vivitrol treatment is not entirely understood, preclinical data suggests that occupation of the opioid receptors results in the blockade of the neurotransmitters in the brain that are believed to be involved with alcohol dependence. This blockade may result in the reduction in alcohol consumption observed in patients treated with Vivitrol.

Vivitrol questions
Q. Is Vivitrol as good as kudzu herb for alcohol treatment?
   A. There has not been a comparison study between Vivitrol and kudzu, therefore it is difficult to say.

Q. Can Vivitrol be taken the same day as an ahcc supplement?
   A. We have not seen any studies with this combination, so it is difficult to say for sure.